Undisclosed Cardiovascular Program
Cardiovascular Disease
Pre-clinicalActive
Key Facts
About inQB8 Medical Technologies
inQB8 Medical Technologies is a pre-revenue, private biotech firm developing novel cardiovascular medical devices, likely incorporating drug delivery mechanisms. Founded in 2016 and headquartered in the major life sciences hub of San Diego, the company is in a stealth or early R&D phase, as evidenced by its minimal public-facing information and 'website launching soon' placeholder. The company's focus on the high-value cardiovascular market positions it to address conditions like coronary artery disease, heart failure, or structural heart disorders, though specific pipeline details remain undisclosed.
View full company profileTherapeutic Areas
Other Cardiovascular Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Manocept Diagnostic | Navidea Biopharmaceuticals | Research |
| Undisclosed Therapeutic Program(s) | HeartcoR Solutions | Pre-clinical |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Undisclosed Cardiovascular Device Program | Transluminal Technologies | Pre-clinical |
| iPSC-CM Cell Therapy | Khloris Biosciences | Research |
| Clinical Trial Integration | Aktiia | Various |
| Cardiovascular Disease Study | Arizona Research Center | Not Specified |
| Cardiovascular Clinical Trials | PanThera Bio | Not Specified |
| Undisclosed | Zecardio Therapeutics | Discovery/Pre-clinical |
| HDL/LDL Regulation | Alpha-1 Biologics | Pre-clinical |
| Cardiovascular Program | Helixomer | Research |
| Undisclosed Cardiovascular Program(s) | Salubris Biotherapeutics | Clinical-stage (phase unspecified) |